Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hennes

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Cancers|January 28, 2026
Nuclear Imaging in Renal Cell Carcinoma: Current Evidence and Clinical ApplicationsAbdullah Al-Khanaty, Shane Qin, Carlos Delgado, et al.
Cancers|March 28, 2026
Quality and Usability of Prostate Cancer Information Generated by Artificial Intelligence Chatbots: A Comparative AnalysisAbdullah Al-Khanaty, Jordan Santucci, David Hennes, et al.
The Lancet. Oncology|June 10, 2026
Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trialJames P Buteau, Daniel Moon, Michael T Fahey, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Cancers|January 28, 2026
Nuclear Imaging in Renal Cell Carcinoma: Current Evidence and Clinical ApplicationsAbdullah Al-Khanaty, Shane Qin, Carlos Delgado, et al.
Cancers|March 28, 2026
Quality and Usability of Prostate Cancer Information Generated by Artificial Intelligence Chatbots: A Comparative AnalysisAbdullah Al-Khanaty, Jordan Santucci, David Hennes, et al.
The Lancet. Oncology|June 10, 2026
Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trialJames P Buteau, Daniel Moon, Michael T Fahey, et al.
Pageof 3